TY  - GEN
AU  - Esteva,Francisco J
AU  - Wang,Jing
AU  - Lin,Feng
AU  - Mejia,Jaime A
AU  - Yan,Kai
AU  - Altundag,Kadri
AU  - Valero,Vicente
AU  - Buzdar,Aman U
AU  - Hortobagyi,Gabriel N
AU  - Symmans,W Fraser
AU  - Pusztai,Lajos
TI  - CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
SN  - 1465-542X
PY  - 2008///0306
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - Biopsy, Fine-Needle
KW  - Breast Neoplasms
KW  - drug therapy
KW  - CD40 Antigens
KW  - Cyclophosphamide
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Gene Expression Profiling
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Mastectomy
KW  - methods
KW  - Mastectomy, Modified Radical
KW  - Mastectomy, Segmental
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Neoplasm, Residual
KW  - Paclitaxel
KW  - Predictive Value of Tests
KW  - RNA, Messenger
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Signal Transduction
KW  - Transcription, Genetic
KW  - Trastuzumab
KW  - Treatment Outcome
KW  - Up-Regulation
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/bcr1836
ER  -